Fluid therapy in the critically ill patient - Beliefs and hard evidence in 2010;Volumenersatz beim kritisch kranken - Glaube und evidenz 2010

Anasthesiologie und Intensivmedizin

Volumn 51, Issue 4, 2010, Pages 219-230

  Hartog, C ^a   Bauer, M ^a   Reinhart, K ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Colloid Solutions; Critical Care; Crystalloid Solutions; Fluid Therapy; Risk

Indexed keywords

DEXTRAN; GELATIN; HETASTARCH; HUMAN ALBUMIN;

BLOOD CLOTTING DISORDER; COLLOID; CRITICALLY ILL PATIENT; CRYSTALLOID; ELECTROLYTE BALANCE; FLUID THERAPY; HEMODYNAMICS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; RESUSCITATION; REVIEW;

EID: 77951699148     PISSN: 01705334     EISSN: 14390256     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2009:CD000567.
2. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-916. (Pubitemid 32247279)
3. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139.
4. Zarychanski R, Turgeon AF, Fergusson DA, Cook DJ, Hebert P, Bagshaw SM, et al. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 2009;3:E196-209.
5. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008;8:1.
6. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010:CD007594.
7. Boldt J. PRO: hydroxyethylstarch can be safely used in the intensive care patient - the renal debate. Intensive Care Med 2009;35:1331-1336.
8. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl Starches: Different Products - Different Effects. Anesthesiology 2009;111:187-202.
9. Van Aken H, Jacob M, Westphal M, Zwissler B. Infusionstherapie in der Anästhesiologie und Intensivmedizin: Gestern, heute und morgen. Anästh Intensivmed 2009;50:338-345.
10. Rivers EP, Nguyen HB, Huang DT, Donnino M. Early goal-directed therapy. Crit Care Med 2004;32:314-315
11. Alderson P, Schierhout G, Roberts I, Bunn F. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2000:CD000567.
12. Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2004:CD000567.
13. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ 1998;317:235-240. (Pubitemid 28334148)
14. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;135:149-164.
15. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-2256. (Pubitemid 38669207)
16. Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005;353:877-889. (Pubitemid 41247927)
17. Upadhyay M, Singhi S, Murlidharan J, Kaur N, Majumdar S. Randomized evaluation of fluid resuscitation with crystalloid (saline) and colloid (polymer from degraded gelatin in saline) in pediatric septic shock. Indian Pediatr 2005;42:223-231. (Pubitemid 40461538)
18. Verheij J, van Lingen A, Beishuizen A, Christiaans HM, de Jong JR, Girbes AR et al. Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery. Intensive Care Med 2006;32:1030-1038. (Pubitemid 43952718)
19. Moss GS, Gould SA. Plasma expanders. An update. Am J Surg 1988;155:425-434.
20. Hitosugi T, Saito T, Suzuki S, Kubota I, Shoda E, Shimizu T et al. Hydroxyethyl starch: the effect of molecular weight and degree of substitution on intravascular retention in vivo. Anesth Analg 2007;105:724-728. (Pubitemid 47300851)
21. Zaar M, Lauritzen B, Secher NH, Krantz T, Nielsen HB, Madsen PL, et al. Initial administration of hydroxyethyl starch vs lactat ed Ringer after liver trauma in the pig. Br J Anaesth 2009;102:221-226.
22. van der Heijden M, Verheij J, van Nieuw Amerongen GP, Groeneveld AB. Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. Crit Care Med 2009;37:1275-1281.
23. Verheij J, van Lingen A, Raijmakers PG, Rijnsburger ER, Veerman DP, Wisselink W, et al. Effect of fluid loading with saline or colloids on pulmonary permeability, oedema and lung injury score after cardiac and major vascular surgery. Br J Anaesth 2006;96:21-30. (Pubitemid 43124526)
24. Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2008:CD001319.
25. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348:1620-1622. (Pubitemid 27007061)
26. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 2001;72:527-33; discussion 34.
27. Jonville-Bera AP, Autret-Leca E, Gruel Y. Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 2001;345:622-623. (Pubitemid 32772113)
28. Haynes GR, Havidich JE, Payne KJ. Why the Food and Drug Administration changed the warning label for hetastarch. Anesthesiology 2004;101:560-561.
29. Stander S, Evers S, Metze D, Schmelz M. Neurophysiological evidence for altered sensory function caused by storage of hydroxyethyl starch in cutaneous nerve fibres. Br J Dermatol 2005;152:1085-1086. (Pubitemid 40704970)
30. Auwerda JJ, Wilson JH, Sonneveld P. Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis. Ann Intern Med 2002;137:1013-1014. (Pubitemid 35440253)
31. Schmidt-Hieber M, Loddenkemper C, Schwartz S, Arntz G, Thiel E, Notter M. Hydrops lysosomalis generalisatus - an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 2006;77:83-85.
32. FDA. NDA REVIEW MEMO (MID-CYCLE). US Department of Health and Human Services, Public health service, Food and Drug Administration. 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/NewDrugApplicationsNDAs/UCM083393.pdf. accessed on 13th November, 2009.
33. Davidson IJ. Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 2006;23:721-738.
34. Mahmood A, Gosling P, Vohra RK. Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. Br J Surg 2007;94:427-433. (Pubitemid 46624720)
35. Boldt J, Brosch C, Rohm K, Papsdorf M, Mengistu A. Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. Br J Anaesth 2008;100:457-464. (Pubitemid 351773609)
36. Boldt J, Brosch C, Ducke M, Papsdorf M, Lehmann A. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 2007;35:2740-2746. (Pubitemid 350175770)
37. Boldt J, Brosch C, Rohm K, Lehmann A, Mengistu A, Suttner S. Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg 2008;107:1496-1503.
38. Boldt J, Suttner S, Brosch C, Lehmann A, Mengistu A. Influence on coagulation of a potato-derived hydroxethylstarch (HES 130/0.42) and a maize-derived hydroxethylstarch (HES 130/0.4) in patients undergoing cardiac surgery. Br J Anaesth 2009;102:191-197.
39. Boldt J, Schollhorn T, Munchbach J, Pabsdorf M. A total balanced volume replacement strategy using a new balanced hydroxyethyl starch preparation (6% HES 130/0.42) in patients undergoing major abdominal surgery. Eur J Anaesthesiol 2007;24:267-275. (Pubitemid 46245713)
40. Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE, et al. Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology 2007;106:1120-1127.
41. Ooi JS, Ramzisham AR, Zamrin MD. Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery? Asian Cardiovasc Thorac Ann 2009;17:368-372.
42. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 2007;105:905-917. (Pubitemid 47479300)
43. Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R, et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 2005;101:629-634, table of contents. (Pubitemid 41208482)
44. Kasper SM, Meinert P, Kampe S, Gorg C, Geisen C, Mehlhorn U, et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 2003;99:42-47. (Pubitemid 36799031)
45. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 2008;107:382-390.
46. Sakr Y, Payen D, Reinhart K, Sipmann FS, Zavala E, Bewley J, et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007;98:216-224. (Pubitemid 47072001)
47. Schortgen F, Brochard L. Colloid-induced kidney injury: experimental evidence may help to understand mechanisms. Crit Care 2009;13:130.
48. Schabinski F, Oishi J, Tuche F, Luy A, Sakr Y, Bredle D, et al. Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients. Intensive Care Med 2009;35:1539-1547.
49. Hagne C, Schwarz A, Gaspert A, Giambarba C, Keusch G. HAES in septic shock - sword of Damocles? Schweiz Med Forum 2009;9:304-306.
50. Blasco V, Leone M, Antonini F, Geissler A, Albanese J, Martin C. Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth 2008;100:504-508. (Pubitemid 351773604)
51. Huter L, Simon TP, Weinmann L, Schuerholz T, Reinhart K, Wolf G, et al. Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 2009;13:R23.
52. Schick MA, Isbary TJ, Schlegel N, Brugger J, Waschke J, Muellenbach R, et al. The impact of crystalloid and colloid infusion on the kidney in rodent sepsis. Intensive Care Med 2009.
53. Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, Martin G, et al. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 2009;37:222-232.
54. Schortgen F, Deye N, Brochard L. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 2004;30:2222-2229. (Pubitemid 40174259)
55. Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, et al. Acute renal failure in patients with severe sepsis and septic shock a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008;23:904-909. (Pubitemid 351767542)
56. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004;139:552-563. (Pubitemid 38585756)
57. Boldt J, Lehmann A, Rompert R, Haisch G, Isgro F. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000;14:264-268. (Pubitemid 30415923)
58. Schramko AA, Suojaranta-Ylinen RT, Kuitunen AH, Kukkonen SI, Niemi TT. Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Anesth Analg 2009;108:30-36.
59. Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg 1998;87:989-993. (Pubitemid 28501146)
60. Ahn HJ, Yang M, Gwak MS, Koo MS, Bang SR, Kim GS, et al. Coagulation and biochemical effects of balanced salt-based high molecular weight vs saline-based low molecular weight hydroxyethyl starch solutions during the anhepatic period of liver transplantation. Anaesthesia 2008;63:235-242. (Pubitemid 351257785)
61. Scharbert G, Deusch E, Kress HG, Greher M, Gustorff B, Kozek-Langenecker SA. Inhibition of platelet function by hydroxyethyl starch solutions in chronic pain patients undergoing peridural anesthesia. Anesth Analg 2004;99:823-827, table of contents. (Pubitemid 39100375)
62. Sossdorf M, Marx S, Schaarschmidt B, Otto GP, Claus RA, Reinhart K, et al. HES130/0.4 impairs haemostasis and stimulates pro-inflammatory blood platelet function. Crit Care in press.
63. Förster H. Biochemische Grundlagen zur Verwendung von polymeren Kohlehydraten als Plasmaersatz. Beitr Anaesth Intensivmed 1988;26:27-42.
64. Kasper SM, Stromich A, Kampe S, Radbruch L. Evaluation of a new hydroxyethyl starch solution (HES 130/0.4) in patients undergoing preoperative autologous blood donation. J Clin Anesth 2001;13:486-490. (Pubitemid 33026479)
65. Lukasewitz P, Kroh U, Löwenstein O, Krämer M, Lennartz H. Quantitative Untersuchungen zur Gewebsspeicherung von mittelmolekularer Hydroxyethylstärke 200/0,5 bei Patienten mit Multiorganversagen. J Anästh Intensivbehandl 1998;3. Quartal:42-46.
66. Auwerda JJ, Leebeek FW, Wilson JH, van Diggelen OP, Lam KH, Sonneveld P. Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch. Transfusion 2006;46:1705-1711. (Pubitemid 44435722)
67. Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F. Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 2003;4:331-338. (Pubitemid 37407725)
68. Blanloeil Y, Trossaert M, Rigal JC, Rozec B. [Effects of plasma substitutes on hemostasis]. Ann Fr Anesth Reanim 2002;21:648-667.
69. Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA. Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest 2003;123:1853-1857.
70. Tseng MY, Hutchinson PJ, Kirkpatrick PJ. Effects of fluid therapy following aneurysmal subarachnoid haemorrhage: a prospective clinical study. Br J Neurosurg 2008;22:257-268.
71. Boldt J. Pro: use of colloids in cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:453-456. (Pubitemid 46829896)
72. Haynes GR. Fluid management in cardiac surgery: is one hydroxyethyl starch solution safer than another? J Cardiothorac Vasc Anesth 2006;20:916-917.
73. Hartog C, Reinhart K. CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients. Intensive Care Med 2009;35:1337-1342.
74. Green RS, Hall RI. Con: starches are not preferable to albumin during cardiac surgery: a contrary opinion. J Cardiothorac Vasc Anesth 2008;22:485-491.
75. Lee WH, Jr., Cooper N, Weidner MG, Jr., Murner ES. Clinical evaluation of a new plasma expander hydroxyethyl starch. J Trauma 1968;8:381-393.
76. Thompson WL, Jr. Hydroxyethyl starch. Prog Clin Biol Res 1978;19:283-292
77. Departement of health and human services, Food and Drug Administration, 21 CFR Part 216 [Docket No. 98N-0655] List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness Federal Register: October 8, 1998 (Volume 63, Number 195) pages 54082-54089. [wwwdocument]http://www.fda.gov/ohrms/dockets/98fr/100898b.txt (accessed on 3 February 2009).
78. Levi M, Jonge E. Clinical relevance of the effects of plasma expanders on coagulation. Semin Thromb Hemost 2007;33:810-815. (Pubitemid 351158449)
79. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008;51:491-503. (Pubitemid 351273478)
80. Disa JJ, Polvora VP, Pusic AL, Singh B, Cordeiro PG. Dextran-related complications in head and neck microsurgery: do the benefits outweigh the risks? A prospective randomized analysis. Plast Reconstr Surg 2003;112:1534-1539. (Pubitemid 39202100)
81. Hartog C, Bloos F, Brunkhorst F, Bogatsch H, Engel C, Reinhart K, et al. Current practice of volume therapy in patients with severe sepsis - results from a national sepsis prevalence study. Abstract, 3rd International Congress "Sepsis and Multiorgan Dysfunction", September 9-12, Weimar. Infection 2009;37 (Suppl. 3):54.
82. Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CR, et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 2006;1:e21.
83. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409. (Pubitemid 29362513)
84. Myburgh J, Cooper DJ, Finfer S, Bellomo R, Norton R, Bishop N, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007;357:874-884. (Pubitemid 47347321)
85. Waters JH, Gottlieb A, Schoenwald P, Popovich MJ, Sprung J, Nelson DR. Normal saline versus lactated Ringer's solution for intraoperative fluid management in patients undergoing abdominal aortic aneurysm repair: an outcome study. Anesth Analg 2001;93:817-822. (Pubitemid 32905961)
86. Lobo DN, Macafee DA, Allison SP. How perioperative fluid bal ance influences postoperative outcomes. Best Pract Res Clin Anaesthesiol 2006;20:439-455.
87. Feinstein AJ, Patel MB, Sanui M, Cohn SM, Majetschak M, Proctor KG. Resuscitation with pressors after traumatic brain injury. J Am Coll Surg 2005;201:536-545. (Pubitemid 41393074)
88. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564-2575. (Pubitemid 43882352)
89. Balogh Z, McKinley BA, Cocanour CS, Kozar RA, Valdivia A, Sailors RM, et al. Supranormal trauma resuscitation causes more cases of abdominal compartment syndrome. Arch Surg 2003;138:637-642; discussion 42-43. (Pubitemid 36666096)
90. O'Mara MS, Slater H, Goldfarb IW, Caushaj PF. A prospective, randomized evaluation of intra-abdominal pressures with crystalloid and colloid resuscitation in burn patients. J Trauma 2005;58:1011-1018.
91. Madigan MC, Kemp CD, Johnson JC, Cotton BA. Secondary abdominal compartment syndrome after severe extremity injury: are early, aggressive fluid resuscitation strategies to blame? J Trauma 2008;64:280-285.
92. Frey L, Kesel K, Pruckner S, Pacheco A, Welte M, Messmer K. Is sodium acetate dextran superior to sodium chloride dextran for small volume resuscitation from traumatic hemorrhagic shock? Anesth Analg 1994;79:517-524.
93. Heering P, Ivens K, Thumer O, Morgera S, Heintzen M, Passlick- Deetjen J, et al. The use of different buffers during continuous hemofiltration in critically ill patients with acute renal failure. Intensive Care Med 1999;25:1244-1251.